Cargando…

Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment

Detalles Bibliográficos
Autores principales:	Lasagna, A., Bergami, F., Lilleri, D., Percivalle, E., Quaccini, M., Comolli, G., Sarasini, A., Sammartino, J.C., Ferrari, A., Arena, F., Cicognini, D., Schiavo, R., Lo Cascio, G., Baldanti, F., Pedrazzoli, P., Cassaniti, I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Society for Medical Oncology. Published by Elsevier Ltd. 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9341169/ https://www.ncbi.nlm.nih.gov/pubmed/35926815 http://dx.doi.org/10.1016/j.annonc.2022.07.012

Ejemplares similares

Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern
por: Lasagna, A., et al.
Publicado: (2022)

Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study
por: Lasagna, A., et al.
Publicado: (2022)

Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up
por: Lasagna, A., et al.
Publicado: (2021)

A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study
por: Lasagna, A., et al.
Publicado: (2021)

Persistence of Immune Response Elicited by Three Doses of mRNA Vaccine against SARS-CoV-2 in a Cohort of Patients with Solid Tumors: A One-Year Follow-Up
por: Lasagna, Angioletta, et al.
Publicado: (2023)

Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study
por: Cassaniti, Irene, et al.
Publicado: (2022)

Effect of a Third Dose of SARS-CoV-2 mRNA BNT162b2 Vaccine on Humoral and Cellular Responses and Serum Anti-HLA Antibodies in Kidney Transplant Recipients
por: Cassaniti, Irene, et al.
Publicado: (2022)

Immune Response to BNT162b2 in Solid Organ Transplant Recipients: Negative Impact of Mycophenolate and High Responsiveness of SARS-CoV-2 Recovered Subjects against Delta Variant
por: Cassaniti, Irene, et al.
Publicado: (2021)

Differential Kinetics of Effector and Memory Responses Induced by Three Doses of SARS-CoV-2 mRNA Vaccine in a Cohort of Healthcare Workers
por: Bergami, Federica, et al.
Publicado: (2022)

Effectiveness of the available early therapies in reducing severe COVID-19 in non-hospitalized patients with solid tumors on active treatment
por: Lasagna, Angioletta, et al.
Publicado: (2022)

Evaluation of the Neutralizing Antibodies Response against 14 SARS-CoV-2 Variants in BNT162b2 Vaccinated Naïve and COVID-19 Positive Healthcare Workers from a Northern Italian Hospital
por: Sammartino, Josè Camilla, et al.
Publicado: (2022)

mRNA BNT162b Vaccine Elicited Higher Antibody and CD4(+) T-Cell Responses than Patients with Mild COVID-19
por: Zavaglio, Federica, et al.
Publicado: (2022)

Characterization of Varicella-Zoster (VZV) Specific T Cell Response in Healthy Subjects and Transplanted Patients by Using Enzyme Linked Immunospot (ELISpot) Assays
por: Cassaniti, Irene, et al.
Publicado: (2021)

Vaccination for herpes zoster in patients with solid tumors: a position paper on the behalf of the Associazione Italiana di Oncologia Medica (AIOM)
por: Pedrazzoli, P., et al.
Publicado: (2022)

Incidence of SARS-CoV-2 infection in health care workers from Northern Italy based on antibody status: immune protection from secondary infection- A retrospective observational case-controlled study
por: Rovida, Francesca, et al.
Publicado: (2021)

Association between Vitamin D Serum Levels and Immune Response to the BNT162b2 Vaccine for SARS-CoV-2
por: Zelini, Paola, et al.
Publicado: (2022)

West Nile or Usutu Virus? A Three-Year Follow-Up of Humoral and Cellular Response in a Group of Asymptomatic Blood Donors
por: Percivalle, Elena, et al.
Publicado: (2020)

Authors’ response: COVID-19: how accurate are seroprevalence studies?
por: Cassaniti, Irene, et al.
Publicado: (2020)

Occult hepatitis B in patients with cancer during immunotherapy with or without chemotherapy: A real-life retrospective single-center cohort study
por: Lasagna, Angioletta, et al.
Publicado: (2023)

SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers
por: Rovida, Francesca, et al.
Publicado: (2021)

Macrophages and Monocytes: “Trojan Horses” in COVID-19
por: Percivalle, Elena, et al.
Publicado: (2021)

Performance of Whole Blood Stimulation Assays for the Quantification of SARS-CoV-2 Specific T-Cell Response: A Cross-Sectional Study
por: Bergami, Federica, et al.
Publicado: (2022)

Boosting capacity of a fourth dose BNT162b2 in cancer patients
por: Debie, Yana, et al.
Publicado: (2023)

SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice
por: Kim, Eun, et al.
Publicado: (2023)

The Humoral Response of Patients With Cancer to Breakthrough COVID-19 Infection or the Fourth BNT162b2 Vaccine Dose
por: Cohen, Idan, et al.
Publicado: (2023)

Protection by a Fourth Dose of BNT162b2 against Omicron in Israel
por: Bar-On, Yinon M., et al.
Publicado: (2022)

Humoral and T-Cell Response before and after a Fourth BNT162b2 Vaccine Dose in Adults ≥60 Years
por: Bar-Haim, Erez, et al.
Publicado: (2022)

Blunted humoral immune response to the fourth dose of BNT162b2 COVID-19 vaccine in patients undergoing hemodialysis
por: Kanai, Daisuke, et al.
Publicado: (2023)

Fourth BNT162b2 vaccination neutralization of omicron infection after heart transplantation
por: Peled, Yael, et al.
Publicado: (2022)

Duration of humoral response to the third dose of BNT162b2 vaccine in patients with solid cancer: Is fourth dose urgently needed?
por: Di Noia, Vincenzo, et al.
Publicado: (2022)

Vaccination for seasonal influenza, pneumococcal infection and SARS-CoV-2 in patients with solid tumors: recommendations of the Associazione Italiana di Oncologia Medica (AIOM)
por: Pedrazzoli, P., et al.
Publicado: (2023)

SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex vivo ELISpot assay
por: Cassaniti, Irene, et al.
Publicado: (2021)

Zika Virus Infection in Pregnancy: Advanced Diagnostic Approaches in Dengue-Naive and Dengue-Experienced Pregnant Women and Possible Implication for Cross-Reactivity and Cross-Protection
por: Zavattoni, Maurizio, et al.
Publicado: (2019)

Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
por: Magen, Ori, et al.
Publicado: (2022)

Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose
por: Canetti, Michal, et al.
Publicado: (2022)

Serum and breastmilk SARS-CoV-2 specific antibodies following BNT162b2 vaccine: prolonged protection from SARS-CoV-2 in newborns and older children
por: Ricciardi, Alessandra, et al.
Publicado: (2022)

Changing circulation rate of human metapneumovirus strains and types among hospitalized pediatric patients during three consecutive winter-spring seasons
por: Gerna, G., et al.
Publicado: (2005)

Thirteen Years of Phleboviruses Circulation in Lombardy, a Northern Italy Region
por: Percivalle, Elena, et al.
Publicado: (2021)

Clinical recrudescence of chronic untreated P. malariae infection after BNT162b2 CoVID-19 vaccine
por: Ciusa, G., et al.
Publicado: (2022)

Humoral Response and SARS-CoV-2 Infection Risk following the Third and Fourth Doses of the BNT162b2 Vaccine in Dialysis Patients
por: Einbinder, Yael, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7nd389lequhif5ejq81qsamgjr